Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine ...

Osaka Metropolitan University-led researchers verified the therapeutic effects of plasma-activated medium on synovial sarcoma ...

Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an ...